“Medical Utilization Surrounding Initial Opioid-Related Diagnoses by Coding Method”

BHIPeer Reviewed Articles

The American Journal of Managed Care, February 2020

A budget impact analysis was conducted from a U.S. commercial payer perspective over a 1-year time horizon with patients who received the implant or revision ESS. Primary outcomes of interest were annual total and per-member per-month (PMPM) direct health care costs. Costs were estimated using a decision analysis model, assuming 50% implant utilization as an alternative to revision ESS in eligible patients, with other levels (25%, 75%) also considered. The model utilized the results of a recently published analysis of 86,052 patients in the Blue Health Intelligence® database, results from published clinical trials evaluating the implant, a literature review, and published Medicare national payment amounts.